Increased demand for depot, depot-related drug distribution, and patient-centric services continues to inspire investment in infrastructure, pharmaceutical expertise and project management capability.
In 2017, the company expanded its market coverage from 148 to 155 countries countries, and added more than 120 new pharmaceutical, manufacturing, and clinical research clients.
Additionaly, Marken doubled the volume of work in its ten GMP-certified depots, tripled the volume of direct-to-patient (DTO) shipments, and expanded DTP into 50 countries.
The company also opened a new headquarters in Research Triangle Park, North Carolina and expanded its facility footprint to 47 locations.
Marken, a wholly owned subsidiary of UPS, is dedicated to the pharmaceutical and life sciences industries.
The company's more than 800 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 220 countries.
Additional services include biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA